Opthea Limited (OPT)

NASDAQ: OPT · IEX Real-Time Price · USD
5.50
+0.10 (1.81%)
At close: Jun 24, 2022 1:47 PM
5.76
+0.26 (4.73%)
After-hours: Jun 24, 2022 4:00 PM EDT
1.81%
Market Cap 264.88M
Revenue (ttm) -110,331
Net Income (ttm) -34.34M
Shares Out 48.16M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE 6.73
Dividend n/a
Ex-Dividend Date n/a
Volume 2,740
Open 5.97
Previous Close 5.40
Day's Range 5.50 - 6.22
52-Week Range 4.73 - 8.73
Beta 0.12
Analysts Buy
Price Target 8.94 (+62.5%)
Earnings Date n/a

About OPT

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ... [Read more...]

Industry Biotechnology
IPO Date Oct 16, 2020
CEO Megan Baldwin
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol OPT
Full Company Profile

Financial Performance

In 2021, Opthea's revenue was 68,613, an increase of 16.17% compared to the previous year's 59,061. Losses were -45.34 million, 307.7% more than in 2020.

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for OPT stock is "Buy." The 12-month stock price forecast is 8.94, which is an increase of 62.55% from the latest price.

Price Target
$8.94
(62.55% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Opthea To Present at Upcoming Investor Conferences

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal d...

Opthea Presentation at The Retina World Congress 2022

MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressi...

Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO...

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...

Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...

Opthea strengthens its Board of Directors

Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of Shareholders Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmolo...

Opthea To Present at Oppenheimer's 32nd Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...

Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer

MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progres...

Opthea Shares OPT-302 data In Patients With Subtype Of Age-Related Macular Degeneration

Opthea Limited's (NASDAQ: OPT) OPT-302 data were presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference.  The data presented was a prespecified subgroup ana...

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea's Phase 2b clinical trial of OPT-302 in combination with ranibizumab...

Opthea To Present at SVB Leerink Global Healthcare Conference

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea Receives A$6.6 m R&D Tax Incentive

MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference

MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal ...

Opthea Appoints Chief Commercial Officer to Lead Commercialization of OPT-302 for Wet AMD

MELBOURNE, Australia, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea Granted Chinese Patent Covering OPT-302

MELBOURNE, Australia, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD

MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea To Present at September Investor Conferences

MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...

Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights

Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD)

Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada

MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Why Opthea Stock Skyrocketed Today

The big gain appears to be a sympathy move related to positive news for another drugmaker.

Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors

MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...

Opthea Company Secretary Resignation

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Co...

Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD

MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...

Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD

MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...

Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...